ALK and non-small cell lung carcinoma: Two out of three advanced NSCLC patients harbour driver genetic alterations, including KRAS, BRAF, EGFR, MET and ERBB2 mutations or ALK, ROS1, RET and NTRK genomic rearrangements [2].